Biotech

All Articles

Gilead spends J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences almost an FDA decision for its own liver disease medicine seladelpar, th...

' All hands on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can view the companies setting up tents at basecamp responsible...

Entero giving up team, abandoning office and stopping R&ampD

.Bed mattress Liquidators has actually switched Entero Therapies white as a sheet. The collector bou...

Exelixis goes down ADC after determining it is actually no suit for Tivdak

.Exelixis is actually quiting on its own cells aspect (TF)- targeting antibody-drug conjugate after ...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 weeks after Roche's Genentech device left an SHP2 inhibitor pact, Relay Rehab has confirmed that ...

Stoke's Dravet disorder med launched of predisposed medical grip

.Stoke Rehabs' Dravet disorder medication has actually been devoid of a partial hold, removing the w...

Fierce Biotech's Gabrielle Masson offers Brutal 15 at NYSE

.Ferocious Biotech Partner Publisher Gabrielle Masson presented the 2024 course of Intense 15 winner...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH prospect

.Novo Nordisk has actually axed its once-monthly double GLP-1/ GIP receptor agonist, ending (PDF) pr...

Daiichi pays out Merck $170M to develop bronchi cancer cells T-cell engager contract

.Merck &amp Co. has actually swiftly recouped several of the expenses of its Harp on Therapies acqui...

BioMarin stops preclinical gene treatment for heart disease

.After BioMarin administered a spring season well-maintained of its own pipe in April, the company h...